Bill Ackman Prepares for 2026 Pershing Square IPO, FT Reports

Apple's latest release, the iPhone Air, has experienced disappointing early sales, as consumers appear to prioritize better value and performance over the device's slim design. This trend indicates a potential shift in consumer preferences within the smartphone market.

Bitcoin's recent decline has raised alarms in the cryptocurrency market, indicating potential instability as it falls below $100,000, reversing earlier gains. This downturn has been marked by a series of losses, including a 12-day consecutive drop, reflecting a broader risk-off sentiment among investors.

The Kremlin has devised a strategy to distance President Putin from the unpopular VAT tax increase, instructing state-controlled media to avoid linking him personally to the rise. This move comes amid growing discontent among the Russian populace regarding economic policies.

President Donald Trump's latest diplomatic efforts in Ukraine focus on securing financial agreements as part of his peacemaking initiatives. This approach reflects his ongoing strategy to leverage dealmaking in shaping U.S. foreign policy.

Bill Ackman is reportedly planning an initial public offering (IPO) for his hedge fund, Pershing Square Capital Management, in early 2026. This move has been anticipated within the investment community and is seen as a significant step for Ackman, a prominent figure in finance. The Financial Times provided the report, citing sources familiar with the situation.

Judge Leonie Brinkema expressed reluctance to mandate a forced sale of Google's advertising business in the ongoing US monopoly case, suggesting that such a dramatic action may not be easily enforceable.

Billionaire investor Bill Ackman is planning to take his hedge fund, Pershing Square, public as early as the first quarter of 2026. This move marks a significant step for Ackman, who has been a prominent figure in the investment community.

Eli Lilly has become the first pharmaceutical company to achieve a market value of $1 trillion, driven by a nearly 40% surge in its shares this year. This growth is largely attributed to the strong demand for its weight-loss and diabetes medications, particularly GLP-1 drugs.